Table 1.

Proportions of SLE Medicaid Patients Newly Initiating Hydroxychloroquine in 29 U.S. States, 2000-2010, who received Baseline Ophthalmologic Examinations (30 days prior through one year after first prescription fill)

	Primary Analysis, n= 12,755	Sensitivity Analysis excluding those with diabetes, cataracts or and glaucoma during the preceding 12 months, n= 10,836	Sensitivity Analysis excluding those with established patient codes, n=10,453	Sensitivity Analysis allowing 6 months prior through 18 months after first prescription fill, n= 12,755
Recommended Retinal Examinations*, %	4,148 (32.5)	3,387 (31.3)	1,846 (17.7)	5,680 (44.5)
Humphrey Visual Field Test and Other Additional Optional Examinations†, %	3,093 (24.3)	2,478 (22.9)	1,764 (16.9)	4,096 (32.1)
> 1 of above examinations, %	5,099 (40.0)	4,154 (38.3)	2,797 (26.8)	6,665 (52.3)

^*Recommended dilated retinal examinations per American Academy of Ophthalmology guidelines 2002 and American College of Rheumatology 2009.

^†Optional eye exams include visual field exams (Humphrey tests), fundus photography, fluorescein angiography, electroretinogram (ERG), electro-oculogram (EOG), extended color vision examination, and spectral domain optimal coherence tomography (SD-OCT). Definitions of these examinations based on Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) Codes found in Supplementary Table 1.